Bringing the Oncology Community Together
Giants of Cancer Care 2015
Enzalutamide Improves PFS Over Bicalutamide in mCRPC
Enzalutamide increased progression-free survival (PFS) by nearly 10 months compared with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Read More >>
Two Studies Explore Role of Radiation, Bisphosphonates in Prostate Cancer Care
Dendreon Revenue Rises, Despite Restructuring
Should a Lower-Grade Prostate Tumor Be Called Cancer?
Medicare Reimburses 3 Prostate Cancer Diagnostic Tests
Gene Points to Aggressive Gleason 7 Prostate Cancer
There’s No Place Like a Medical Home: Premier Medical Group Focuses on Full-scale Patient-Centered Care
View More >>
- A Network of Your Peers
View more >>
Dr. Tward on Abbreviated Course ADT for Prostate Cancer
Multiparametric MRI Biopsies: Poised for Widespread Adoption?
Dr. Sieber on the CHAARTED Trial
Most Popular Right Now
Tweets by @OncLive
Genomic Testing for Newly Diagnosed Low-Risk Prostate Cancer
E. David Crawford, MD, Steven E. Canfield, MD, Marc A. Dall'Era, MD, and Neal Shore, MD, discuss genomic testing for newly diagnosed, low-risk prostate cancer.
Updates in the Management of CRPC
Moderated by Raoul S. Concepcion, MD, this panel discussion includes expert perspectives from Neal D. Shore, MD, Paul R. Sieber, MD, E. David Crawford, MD, and Mark S. Austenfeld, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.